Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding

Health Technology Assessment

Volumn 11, Issue 51, 2007, Pages

  Leontiadis, G I ^a,k   Sreedharan, A ^b   Dorward, S ^c   Barton, P ^d   Delaney, B ^d   Howden, C W ^e   Orhewere, M ^f   Gisbert, J ^g   Sharma, V K ^h   Rostom, A ⁱ   Moayyedi, P ^j   Forman, D ^c  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b LINCOLN COUNTY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e NORTHWESTERN UNIVERSITY   (United States)

^f South Birmingham Primary Care Trust   (United Kingdom)

^g HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^h MAYO CLINIC   (United States)

ⁱ UNIVERSITY OF CALGARY   (Canada)

^j MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^k DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; ANTACID AGENT; BISMUTH; BISMUTH CITRATE; BISMUTH SALICYLATE; CELECOXIB; CIMETIDINE; CLARITHROMYCIN; DICLOFENAC; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; MANNITOL; METRONIDAZOLE; MISOPROSTOL; NAPROXEN; NIZATIDINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; RANITIDINE; SOMATOSTATIN; STOMACH SECRETION INHIBITOR; SUCRALFATE; TETRACYCLINE; TRANEXAMIC ACID; UNINDEXED DRUG;

ABDOMINAL PAIN; BACKACHE; BLOOD TRANSFUSION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONFUSION; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DRUG COST; DRUG EFFICACY; DRUG INDUCED CANCER; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUODENUM ULCER; DYSPEPSIA; DYSPNEA; FEVER; FLATULENCE; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SURGERY; HEALTH CARE COST; HEART FAILURE; HEART INFARCTION; HEART PALPITATION; HELICOBACTER INFECTION; HUMAN; INJECTION SITE REACTION; LEG PAIN; LONG TERM CARE; LUNG EMBOLISM; META ANALYSIS; MORNING DOSAGE; MORTALITY; MYALGIA; NAUSEA; PEPTIC ULCER BLEEDING; RECURRENT DISEASE; REVIEW; RISK REDUCTION; SCLEROTHERAPY; STOMACH ULCER; SYSTEMATIC REVIEW; TACHYCARDIA; THROMBOPHLEBITIS; UPPER GASTROINTESTINAL BLEEDING; ACUTE DISEASE; AGED; BIBLIOGRAPHIC DATABASE; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DRUG EFFECT; ECONOMICS; HELICOBACTER PYLORI; MIDDLE AGED; ORGANIZATION; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; UPPER GASTROINTESTINAL TRACT;

ACUTE DISEASE; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CONGRESSES AS TOPIC; COST-BENEFIT ANALYSIS; DATABASES, BIBLIOGRAPHIC; DUODENAL ULCER; ENDOSCOPY, GASTROINTESTINAL; GASTROINTESTINAL HEMORRHAGE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HISTAMINE H2 ANTAGONISTS; HUMANS; MIDDLE AGED; PEPTIC ULCER HEMORRHAGE; PROTON PUMP INHIBITORS; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; UPPER GASTROINTESTINAL TRACT;

EID: 38949179599     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta11510     Document Type: Review

References (266)

1. Laine L. Peterson WL. Bleeding peptic ulcer. N Engl J Med 1994; 331:717-27.
2. Mignon M, Penston JG, Deltenre M, Ruszniewski P, Dobrill G. Natural history of duodenal ulcer disease: Are we at a turning point? Gastroenterol Int 1994;7:95-113.
3. Petersen H, Kristensen P, Johannessen T, Kleveland PM, Dybdahl JH, Myrvold H. The natural course of peptic ulcer disease and its predictors. Scand J Gastroenterol 1995;30:17-24.
4. Laine L, Peterson WL. Helicobacter pylori and complicated ulcer disease. Am J Med 1996; 100:52s-57s.
5. Gilbert DA. Epidemiology of upper gastrointestinal bleeding. Gastrointest Endosc 1990; 36 (Suppl):S8-13.
6. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA 1994;272:65-9.
7. Lim CH, Vani D, Shah SG, Everett SM, Rembacken BJ. The outcome of suspected upper gastrointestinal bleeding with 24-hour access to upper gastrointestinal endoscopy: a prospective cohort study. Endoscopy 2006;38:581-5.
8. Rorkall TA. Logan RFA, Devlin HB, Northfield TC. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom. BMJ 1995;311:222-6.
9. Khuroo MS, Yattoo GN, Javid G. Khan BA, Shah AA, Gulzar GM, et al. A comparison of omeprazole and placebo for bleeding peptic ulcer. N Engl J Med 1997;336:1054-8.
10. Allan RN, Dykes PW. A study of the factors influencing mortality rates from gastrointestinal haemorrhage. Q J Med 1976;54:533-50.
11. Cook DJ, Guyatt GH, Salena BJ, Laine LA. Endoscopic therapy for acute nonvariceal upper gastrointestinal haemorrhage: a meta-analysis. Gastroenterology 1992;102:139-48.
12. Barkun A, Bardou M, Marshall JK, Nonvariceal Upper GI Bleeding Consensus Conference Group. Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2003;39:843-57.
13. Kolkman JJ, Meuwissen SGM. A review on treatment of bleeding peptic ulcer: a collaborative task of gastroenterologist and surgeon. Scand J Castroenterol 1996;31 (Suppl 218):16-25.
14. Green FJ, Kaplan MM, Curtis LE, Levine PH. Effects of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor to prolonged gastro duodenal mucosal haemorrhage. Gastroenterology 1978;74:38-43.
15. 2 antagonists in acute upper gastrointestinal haemorrhage. Implications of randomized trials. N Engl J Med 1985;313:660-6.
16. 2-receptor antagonists in bleeding peptic ulcer. Aliment Pharmacol Ther 2002;16:1137-42.
17. Hasselgren G, Keelan M, Kirdeikis P, Lee J, Rohss K, Sinclair P, et al. Optimization of acid suppression for patients with peptic ulcer bleeding: an intragastric pH-metry study with omeprazole. Eur J Gastroenterol Hepatol 1998;10:601-6.
18. Brunner G, Luna P, Hartmann M, Wurst W. Optimizing the intragastric pH as a supportive. therapy in upper GI bleeding. Yale J Biol Med 1996;69:225-31.
19. 2-antagonists: a meta-analysis of their efficacy in treating bleeding peptic ulcer. Aliment Pharmacol 2001;15:917-26.
20. Leontiadis GI, McIntyre L, Sharma VK, Howden CW. Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev 2004;(3):CD002094.
21. Leontiadis GI, Sharma VY, Howden CW. Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding. BMJ 2005;330:568-70.
22. Khuroo MS, Khuroo MS, Farahat KL, Kagevi IE. Treatment with proton pump inhibitors in acute non-variceal upper gastrointestinal bleeding; a meta-analysis. J Gastroenterol Hepatol 2005; 20:11-25.
23. Bardou M, Toubouti Y, Benhaberou-Brun D, Rahme E, Barkun AN. Meta-analysis: proton-pump inhibition in high-risk patients with acute peptic ulcer bleeding. Aliment Pharmacol Ther 2005; 21:677-86.
24. Andriulli, A, Annese V, Caruso N, Pilotto A, Accadia L, Niro AG, et al. Proton-pump inhibitors and outcome of endoscopic hemostasis in bleeding peptic ulcers: a series, of meta-analyses. Am J Gastroenterol 2005;100:207-19.
25. Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev 2006; (1):CD002094.
26. Spiegel BM, Dulai GS, Lim BS, Mann N, Kanwal F, Gralnek IM. The cost-effectiveness and budget impact of intravenous versus oral proton pump inhibitors in peptic ulcer haemorrhage. Clin Gastroenterol Hepatol 2006;4:988-97.
27. Barkun AN, Herba K, Adam V, Kennedy W, Fallone CA, Bardou M. The cost-effectiveness of high-close oral proton pump inhibition after endoscopy in the acute treatment of peptic ulcer bleeding. Aliment Pharmacol Ther 2004;20:195-202.
28. Palmer KR. Non-variceal upper gastrointestinal haemorrhage: guidelines. British Society of Gastroenterology Endoscopy Committee. Gut 2002;51 (Suppl4):iv1-iv6.
29. Murray WR, Cooper G, Laferla G, Rogers P, Archibald M. Maintenance ranitidine treatment after haemorrhage from a duodenal ulcer. A 3-year study. Scand J Gastroenterol 1988;23:183-7.
30. Jensen DM, Cheng S, Kovacs TO, Randall G, Jensen ME, Reedy T, et al. A controlled study of ranitidine for the prevention of recurrent haemorrhage from duodenal ulcer. N Engl J Med 1994; 330:382-6.
31. Ries JF, Miller SR, Spitz PW, Williams CA, Hubert HB, Bloch DA. Identification of patients at risk for gastropathy associated with NSAID use. J Rheumatol 1990;20:12-19.
32. Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 1997; 112:1000-16.
33. Silverstein FE, Graham DY, Senior JR, Davies HW. Struthers BJ, Bittman RM, et at. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:241-9.
34. Stalnikowicz R, Rachmilewitz D. NSAID-induced gastro duodenal damage: is prevention needed? A review and metaanalysis. J Clin Gastroenterol 1993;17:238-43.
35. Smalley WE, Griffin MR. The risks and costs of upper gastrointestinal disease attributable to NSAIDs. Gastroenterol Clin North Am 1996; 25:373-96.
36. Griffin MR, Ray WA, Schaffner W, Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med 1988; 109:359-63.
37. Bollini P, Rodriguez G, Gutthann S. The impact of research quality and study design on epidemiologic estimates of the effect of nonsteroidal anti-inflammatory drugs on upper gastrointestinal tract disease. Arch Intern Med 1992; 152:1289-95.
38. McMahon AD, Evans JM, White G, Murray FE, McGilchrist MM, McDevitt DG, et al. A cohort study (with re-sampled comparator groups) to measure the association between new NSAID prescribing and upper gastrointestinal haemorrhage and perforation. J Clin Epidemiol 1997:50:351-6.
39. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of non-steroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 1991; 115:787-96.
40. Langman MJ, Weil J, Wainright P, Lawson DH, Rawlins MD, Logan RF, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343:1075-8.
41. McDonald TM. Morant SV, Robinson GC. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: Cohort Study. BMJ 1997; 315:1333-7.
42. Armstrong CP, Blower AL. Nonsteroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987; 28:527-32.
43. Larkai EN, Smith JI, Lidsky MD. Gastro duodenal mucosa and dyspeptic symptoms in arthritic patients during chronic non-steroidal anti-inflammatory drug use. Am J Gastroenterol 1987; 82:1153-8.
44. Maetzel A, Ferraz MB, Bombardier C. The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal anti-inflammatory drugs. Arthritis Rheum 1998;41:16-25.
45. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343:1520-8.
46. Silverstein FE, Faich G, Goldstein JL. Simon LS, Pincus T. Whelton A. et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomised controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55.
47. Nielsen OH, Ainsworth M, Csillag C, Rask-Madsen J, Systematic review: coxibs, non-steroidal anti-inflammatory drugs or no cyclooxygenase inhibitors in gastroenterological high-risk patients? Aliment Pharmacol Ther 2006;23:27-33.
48. Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E, et al. Prevention of NSAID-induced gastro duodenal ulcers. Cochrane Database Syst Rev 2002;(4):CD002296.
49. Hooper L, Brown TJ, Elliott R, Payne K, Roberts C, Symmons D. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ 2004; 329:948-52. Epub 8 October 2004.
50. Brown TJ, Hooper L, Elliott RA, Payne K, Webb R, Roberts C, et al. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling. Health Technol Assess 2006; 10(38).
51. Elliott RA, Hooper L, Payne K, Brown TJ, Roberts C, Symmons D. Preventing non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: are older strategies more cost-effective in the general population? Rheumatology 2006; 45:606-13.
52. Girvin B, Rafferty T, Stevenson MR, Johnston GD. Uptake of COX-2 selective inhibitors and influence on NSAID prescribing in Northern Ireland. Pharmacoepidemiol Drug Saf 2004;13:153-7.
53. Singh G, Triadafilopoulos G. Author reply to: Gitlin N, Weaver AL. Response to: appropriate choice of proton pump inhibitor therapy in the prevention and management of NSAID-related gastrointestinal damage. Int J Clin Pract 2006; 60:610-11.
54. Kuipers EJ, Thijs JC, Festen HP. The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther 1995; 9(Suppl 2):59-69.
55. Gisbert JP, Pajares JM. Helicobacter pylori and bleeding peptic ulcer: what is the prevalence of the infection in patients with this complication? Scand J Gastroenterol 2003;38(1):2-9.
56. Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 1996;110:1244-52.
57. Soll AH. Medical treatment of peptic ulcer disease. JAMA 1996; 275:622-9.
58. Gisbert JP, Khorrami S, Carballo E, Calvet X, Gene E, Dominguez-Munoz JE. H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Cochrane Database Syst Rev 2004;(2):CD004062.
59. Sharma VK, Sahai AV, Corder FA, Howden CW. Hellicobacter pylori eradication is superior to ulcer healing with or without maintenance therapy to prevent further ulcer haemorrhage. Aliment Pharmacol Ther 2001;15:1939-47.
60. Ofman J, Wallace J, Badamgarav E, Chiou CF, Herming J, Laine L. The cost-effectiveness of competing strategies for the prevention of recurrent peptic ulcer haemorrhage. Am J Gastroenterol 2002; 97:1941-50.
61. Barton PM, Robinson SM. Modelling in the economic evaluation of health care: selecting the appropriate approach. J Health Serv Res Policy 2004;9:110-18.
62. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-43.
63. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controll Clin Trials 1996; 17:1-12.
64. Greenland S, Robins JM. Estimation of a common effect parameter from sparse follow-up data. Biometrics 1985;41:55-68.
65. L'Abbe KA, Detsky AS, O'Rourke X. Meta-analysis in clinical research. Ann Intern Med 1987; 107:224-33.
66. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controll Clin Trials 1986;7:177-88.
67. Desprez D, Blanc P, Bories JM, Pageaux GP, David XR, Veyrac M, et al. Acute upper gastrointestinal haemorrhage: a preliminary report of a randomised trial comparing intravenous administradon of ranitidine and omeprazole. Gastroenterology 1995;108 Suppl:A82 (abstract).
68. Duvnjak M, Supanc V, Troskot B, Kovacevic I, Antic Z, Hrabar D, et al. Comparison of intravenous pantoprazole with intravenous ranitidine in prevention of rebleeding from gastroduodenal ulcers. Gut 2001;49 (Suppl III) 2379 (abstract).
69. Fried R, Beglinger C, Meier R, Stumpf J, Adler G, Schepp W, et al. Comparison of intravenous pantoprazole with intravenous ranitidine in peptic ulcer bleeding. Gut 1999;45 (Suppl V):A100 (abstract).
70. Barkun A, Racz I, van Rensburg C, Beglinger C, Kupcinskas L, Schaefer-Preuss S, et al. Prevention of peptic ulcer rebleeding using continuous infusion of pantoparzole vs. ranitidine: a multicenter multinational, randomized, double-blind, parallel-group comparison. Gastroenterology 2004;126 (4 Sdppl 2):A-78.
71. Jensen DM, Pace SC, Soffer EF, Mark ME, Comer GM. Lower rebleeding rates in high risk patients treated with IV pantoprazole than IV ranitidine after endoscopic hemostasis in a randomised controlled study. Am J Gastroenterol 2004;99:S296.
72. Brunner-G, Chang J. Intravenous therapy with high doses of ranitidne and omeprazole in critically ill patients with bleeding peptic ulcerations of the upper intestinal tract: an open randomized controlled trial. Digestion 1990; 45:217-25.
73. Cardi M, Muttillo IA, Amadori L, Barillari P, Sanmartino P, Arnone F, et al. [Intravenous omeprazole versus ranitidine in the treatment of hemorrhagic duodenal ulcer: a prospective randomised study]. Ann Chir 1997;51:136-9 (in French).
74. Coraggio F, Rotondano G, Marmo R, Balzanelli AG, Catalano A, Clemente F, et al. Somatostatin in the prevention of recurrent bleeding after endoscopic haemostasis of peptic ulcer haemorrhage: a preliminary report. Eur J Gastroenterol Hepatol 1998;10:673-6.
75. Daneshmend TK, Hawkey CJ, Langman MJ, Logan RG, Wait RP. Omperpazole versus placebo for acute upper gastrointestinal bleeding: Randomised double blind controlled trial. BMJ 1992;304:143-7.
76. Hasselgren G, Lind T, Lundell L, Aadland E, Efskind P, Falk A, et al. Continuous intravenous infusion of omeprazole in elderly patients with peptic ulcer bleeding. Scand J Gastroenterol 1997; 32:328-33.
77. Javid G, Masoodi I, Zargar SA, Khan BA, Yatoo GN, Shah AH, et al. Omeprazole as adjuvant therapy to endoscopic combination injection sclerotherapy for treating bleeding peptic ulcer. Am J Med 2001; 111:280-4.
78. Kaviani MJ, Hashemi MR, Kazemifar AR, Roozitalab S, Mostaghni AA, Merat S, et al. Effect nf oral omeprazole in reducing re-bleeding in bleeding peptic ulcers: a prospective, double-blind, randomized, clinical trial. Aliment Pharmacol Ther 2003;17:211-16.
79. Labenz J, Peitz U, Leusing C, Tillenburg B, Blum AL, Borsch G. Efficacy of primed infusions with high dose ranitidine and omeprazole to maintain high intragastric pH in patients with peptic ulcer bleeding: a prospective randomised controlled study. Gut 1997;40:36-41.
80. Lanas A, Artal A, Blas JM, Arroyo MT, Lopez-Zaborras J, Sainz R. Effect of parenteral omeprazole and ranitidine on gastric pH and the outcome of bleeding, peptic ulcer. J Clin Gastroenterol 1993;21:103-6.
81. Lau JYW, Sung JJY, Lee KKC, Yung M-Y, Wong SKH, Wu JCY, et al. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med 2000; 343:310-16.
82. Lin HJ, Lo WC, Lee FY, Perng CL, Tseng GY. A prospective randomized comparative trial showing that omeprazolle prevents rebleeding in patients with bleeding peptic ulcer after successful ehdoscopic therapy. Arch Intern Med 1998; 158:54-8.
83. Lin HJ, Lo WC, Perng CL, Wang K, Lee FY, Can optimal acid suppression prevent rebleeding in peptic ulcer patients with a non-bleeding visible vessel: a preliminary report of a randomized comparative study. Hepatogastroenterology 1997; 44:1495-7.
84. Michel P, Duhamel C, Bazin B, Raoul JL, Person B, Bigard MA, et al. Lansoprazole versus ranitidine in the prevention of early recurrences of digestive haemorrhages from gastro duodenal ulcers. Randomised double blind multicentre study [Lansoprazole versus ranitidine dans la prévention des récidives précoces des hémorragies digestives ulcéreuses gastro-duodénales. Etude multicentrique randomisée en double aveugle]. Gastroenterol Clin Biol 1994;18:1102-5.
85. Perez Flores R, Garcia Molinero MJ, Herrero Quiros C, Blasco Colmenarajaro MM, Caneiro Alcubilla E, Garcia-Rayo Somoza M, et al. The treatment of upper digestive haemorrhage of peptic origin: intravenous ranitidine versus intravenous omeprazole [Tratamiento de la hemorragia digestiva alta origen peptico: ranitidina intravenosa versus omeprazol intravenoso]. Rev Esp Enferm Dig 1994;86:637-41.
86. Schaffalitzky de Muckadell OB, Havelund T, Harling H, Boesby S, Snel P, Vreeburg EM, et al. Effect of omeprazole on the outcome of endoscopically treated bleeding peptic ulcers. Randomized double-blind placebo-controlled multicentre study. Scand J Gastroenterol 1997; 32:320-7.
87. Sheu BS, Chi CH, Huang CC, Kao AW, Wang YL, Yang HB. Impact of intravenous omeprazole on Helicobacter pylori eradication by triple therapy in patients with peptic ulcer bleeding. Aliment Pharmacol Ther 2002;16:137-43.
88. Villanueva C, Balanzo J, Torras X, Sainz S, Soriano G, Gonzalez D, et al. Omeprazole versus ranitidine as adjunct therapy to endoscopic injection in actively bleeding ulcers, a prospective randomised trial. Endoscopy 1995;27:308-12.
89. Xuan JL. Loseco compared with famotidine in the treatment of uppper gastrointestinal bleeding: clinical analysis of 90 cases. Guangxi Med J 2003; 25:523-9.
90. Artal A. Lanas AA, Barrao ME, Moliner FJ, Bias JM, Lopez J. Valoracion de ranitidina y omeprazol intravenosos por pH-metria gastrica. de 24 horas en hemorragia digestiva por ulcera duodenal [An evaluation of intravenous ranitidine vs. omeprazole in the 24 h pH measurements in bleeding duodenal ulcer]. Rev Esp Enferm Dig 1996;80:191-6.
91. Chilovi F, Piazzi L, Zancanella L, De Guelmi A, Grasso T, Di Fede, et al. Intravenous omeprazole and pantoprazole after endoscopic treatment of bleeding peptic ulcers. Gastrointest Endosc 2003; 57:AB150.
92. Chu XQ, Jia LS. Effects of omeprazole and ranitidine on the treatment of peptic ulcer haemorrhage. J Gastroenterol Hepatol 1993; 8 (Suppl 2):S239.
93. Chua RT, Lin HJ, Wang K, Perng CL, Lo WC, Lee CH, et al. Intravenous omeprazole prevents rebleeding in peptic ulcer patients with a non-bleeding visible vessel: a preliminary report of a randomized controlled study. Chung Hua I Hsueh Tsa Chih (Taipei) 1996; 57:139-45.
94. Dokas SM, Lazaraki GI, Kontoninas Z, Kouklakis GS, Adamidou A, Tsiaousi E, et al. Bolus intravenous omeprazole B.I.D. vs. continuous intravenous omeprazole infusion combined with endoscopic hemostasis in the treatment of peptic ulcer bleeding. Preliminary results. Gut 2004;53 (Suppl VI):A290.
95. Fasseas P, Leybishkis B, Rocca G. Omeprazole versus ranitidine in the medical treatment of acute upper gastrointestinal bleeding: assessment by early repeat endoscopy. Int J Clin Pract 2001; 55:661-4.
96. Focareta R, Ciarleglio A, Piai G, Ievoli F, Forte G. Proton-pump inhibitor and acute peptic ulcer bleeding: effectiveness of oral esomeprazole vs. intravenous omeprazole in reducing the risk of recurrent bleeding. Digest Liver Dis 2004; 36 (Suppl 2):S250.
97. Fried R, Beglinger C, Stumpf J, Adler G, Schepp W, Klein M, et al. Comparison of intravenous pantoprazole with intravenous ranitidine in peptic ulcer bleeding. Gastroenterology 1999;116:A165 (abstract).
98. Goletti O, SF, Lippolis PV, De Negri F, Cavina E. Omeprazole versus ranitidine plus somatostatin in the treatment of severe gastro duodenal bleeding: a prospective, randomized, controlled trial. Ital J Gastroenterol 1994;26:72-4.
99. Grosso C, Rossi A, Gambitta P, Bini M. Zanasi G, Pirone Z, et al. Non-bleeding visible vessel treatment: perendoscopic injection therapy versus omeprazole infusion. Scand J Gastroenterol 1995; 30:872-5.
100. Hawkey GM, Cole AT, McIntyre AS, Long RG, Hawkey CJ. Drug treatments in upper gastrointestinal bleeding: value of endoscopic findings as surrogate end points. Gut 2001; 49:372-9.
101. Lau JYW, Sung JJ Y, Lee KKC, Yung MY, Ng EKN, Sung JJ. Intravenous omeprazole infusion after endoscopic ulcer hemostasis: a double-blind placebo-controlled randomized trial. Gastroenterology 1999; 116:A232.
102. Lin HJ, Lo WC, Lee FY Omeprazole prevents rebleeding in bleeding peptic ulcer patients after endoscopic therapy. Am J Gastroenterol 1996; 91:1918.
103. Lind T, Aadland E, Eriksson S, Fernstrom P, Hasselgren C, Lundell L. Beneficial effects of IV omeprazole in patients with peptic ulcer bleeding. Gastraenterology 1995;108:A150.
104. Maculotti L, Pradella R Comparison of ranitidine, famotidine and omeprazole in the treatment of bleeding duodenal ulcer [Confonto tra ranitidina, famotidina e omeprazolo nel trattamento dell'ulcera duodenale sanguinante]. Minerva Chir 1995;50:279-81.
105. 2 receptor antagonists in the treatment of acute upper non-variceal bleeding. Hepatogastroenterology 1996;43:863-5.
106. Orti E, Canelles P, Quiles F, Zapater R, Cuquerella J, Ariete V, et al. Does the antisecretory agent used affect the evolution of upper digestive haemorrhage? [Affecta a la evolucion de la hemorragia digestiva alata el antisecretor utilizado?]. Rev Esp Enferm Dig 1995;87:427-30.
107. 2 receptor antagonists? Z Gastroenterol 1995;33:431-4.
108. Schaffalitzky de Muckadell OB, Havelund T, Harling H, Boesby S, Snel P, Vreeburg EM, et al. The effect of omeprazole on the outcome of endoscopically treated bleeding peptic ulcers: a randomized double-blind placebo-controlled multicentre study. Neth J Med 1996; 48:A3-4 (abstract).
109. Schonekas H, Ahrens H, Pannewick U, Ell C, Koop H, Petritsch W, et al. Comparison of two doses of intravenous pantoprazole in peptic ulcer bleeding. Gastroenterology 1999;116(4. part 2): A305.
110. Sofia C, Portela F, Gregorio C, Rosa A, Camacho E, Tome L, et al. Endoscopic injection therapy vs. multipolar electrocoagulation vs. laser vs. injection + octreotide vs. injection + omeprazole in the treatment of bleeding peptic ulcers. A prospective randomized study. Hepatogastroenterology 2000; 47:1332-6.
111. Taug SH, Hu W Effect of pantoprazore in the treatment of peptic ulcer. Herald Med 2001; 20:431-2.
112. Tseng GY, Lin HJ, Lin HY, Perng CL, Lee FY, Lo WC, et al. The influence of intravenous omeprazole on intragastric pH and outcomes in patients with peptic ulcer bleeding after successful endoscopic therapy - a prospective randomised comparative trial. Hepatogastroenterolgy 1999; 46:2183-4.
113. Tsukamoto Y. Clinical study on the initial treatment with lansoprazole and recurrence of peptic ulcer disease. Jpn Pharmacol Ther 1997; 25:151-61 (in Japanese).
114. Udd M, Miettinen P, Palmu A, Heikkinen M, Janatiunen E, Pasanen P, et al. Regular-dose versus high-dose omeprazole in peptic ulcer bleeding. A prospective randomized double-blind study. Scand J Gastroenterol 2001;36:1332-8.
115. Uribarrena R, Bajador E, Simon MA, Sabastian JJ, Gomollon F. Omeprazole and cimetidine in the treatment of upper digestive haemorrhage [Omeprazol y cimetidina en el tratamiento de la hemorragia digestiva alta]. Rev Esp Enferm Dig 1994;86:879-83.
116. Wallner G, Ciechanski A, Wesolowski M, Sory A. Misiuna P. Treatment of acute upper gastrointestinal bleeding with intravenous omeprazole or ranitidine. Eur J Clin Res 1996; 8:235-43.
117. Zhao LY, Liu HY, Zhu WN. The short-term efficacy of omeprazole in the treatment of peptic ulcer. Chin J Dig 1990;10:338-40.
118. Zhonglin Y, Sanren L, Huiji W. Effectiveness and safety of pantoprazole i.v. and omeprazole i.v. in the treatment of pateints with peptic ulcer bleeding. J Gastroenterol Hepatol 2002;17:A257 (abstract).
119. Hulagu S, Demirturk L, Gul S, Yazgan Y, Altin M, Danaci M. The effect of omeprazole or ranitidine intravenous on upper gastrointestinal bleeding. Endoskopi J 1995;2:35-42.
120. Lau JY, Leung WK, Wu JC, Chan FK, Wong V, Hung LC, et al. Early administration of high dose intravenous omeprazole prior to endoscopy in patients with upper gastrointestinal bleeding: a double blind placebo controlled randomized trial. Gastroenterology 2005;128 (Suppl 4):A347 (abstract).
121. Bai G, Hu FL, Lu DH, Qin J. Efficacy of intravenous administration of omeprazole in the treatment of upper gastrointestinal haemorrhage caused by peptic ulcer and acute gastric mucosal lesion. J Clin Pharmacol 1995;11:206-9.
122. Colin R, Michel P, Sallerin V. Comparison of the efficacy of lansoprazole and ranitidine in the prevention of early relapse in people with upper gastrointestinal ulcerative haemorrhage with a high risk of early recurrence of rebleeding. A double blind multi centre study. Gastroenterol Clin Biol 1995;17:AI05.
123. Costamagna G, Mutignani M, Perri V, Colombo GM, Bruni A, Gabbrielli A, et al. Lansoprazole in preventing bleeding relapse in upper gastrointestinal non variceal bleeding. Gastroenterology 1998; 114:A95.
124. 2 antagonists? A comparative study. Ann Med 1992; 169-72.
125. Felder LR, Barkin JS. A comparison of omeprazole and placebo for bleeding peptic ulcer. Gastrointest Endosc 1998;47:428-9.
126. Gao Z, Deng C, Yi J. The effect of omeprazole on upper gastrointestinal haemorrhage. Acta Acad Med Hubei 1995;16:223-5.
127. Liu RH, Wei CM, Wang XP, Yin ZZ. The efficacy of losec versus famotidine in the treatment of bleeding duodenal ulcer. Shanghai Med Pharm J 2002;23:199-201.
128. Munkel L, French L. Treatment of bleeding peptic ulcers with omeprazole. J Fam Pract 1997;45:201.
129. Nehme O, Barkin JS. Recurrent ulcer bleeding: is intravenous omeprazole the solution. Am J Gastroenterol 2001;96:594-5.
130. Savides TJ, Pratha V. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. Gastrointest Endosc 2001;54:130-2.
131. Scheurlen M. Peptic ulcer haemorrhage: IV antacid prevents recurrence. Fortschr Med 2000; 142:30.
132. Srinath C. Comparison of omeprazole and placebo for bleeding peptic ulcer. Trop Gastroenterol 1997; 18:115-16.
133. Wu N, Wang SJ, Wang SG, Pan GH. Therapeutic efficacy of pantoprazole on upper gastrointestinal haemorrhage. Chin New Med 2001; 2:1091-2.
134. Vreeburg EM, Terwee CB, Snel P, Rauws EA, Bartelsmarr JF, Meulen JH, et al. Validation of the Rockall risk scoring system in upper gastrointestinal bleeding. Gut 1999;44:331-5.
135. Rockall TA, Logan RFA, Devlin HB, Northfield TC. Infuencing the practice and outcome in acute upper gastrointestinal haemorrhage. Gut 1997; 41:606-11.
136. Netten A, Curtis L. The unit costs of health and social care. Personal Social Services Research Unit. University of Kent, Ganterbury: Personal-Social Services Region Unit; 2006. Available at:http:// www.pssru.ac.uk/pdf/uc/uc2006/uc2006.pdf. Accessed 18 September 2007.
137. National Reference Tables, National Data by Procedure. URL: http: // www.dh.gov.uk/PublicationsAndStatistics. Accessed 18 September 2007.
138. British National Formulary issue 51. BMJ Publishing and Royal London: Pharmaceutical Society; 2006.
139. EuroQoL. URL: http://gs1.g4matics.com/EuroqolPublishWeb/
140. Leontiadis GI. Sharma VK, Howden CW. Enhanced efficacy of proton pump inhibitor therapy for peptic ulcer bleeding in Asia: a post hoc analysis from the Cochrane Collaboration. Aliment Pharmacol Ther 2005;21:1055-61.
141. Arkkila PE, Seppala K, Kosunen U, Haapiaine R, Kivilaaks E, Sippone P, et al. Eradication of Helicobacter pylori improves healing rate and reduces the relapse rate of nonbleeding ulcers in patients with bleeding peptic ulcer. Am J Gastroenterol 2003;98:2149-56.
142. Bataga S, Bratu A. Bancu L, Torok I, Dudea C. The treatment in bleeding duodenal ulcer. Gut 1997;41 (Suppl 3):A167.
143. Graham DY, Hepps KS, Ramirez FC, Lew GM, Saeed ZA. Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease. Scand J Gastroenterol 1993;28:939-42.
144. Jaspersen D, Koerner T, Schorr W, Brennenstuhl M, Raschka C, Hammar CH. Helicobacter pylori eradication reduces the rate of rebleeding in ulcer haemorrhage. Gastrointest Endosc 1995;41:5-7.
145. Lai KC, Hui WM, Wong WM, Wong BC, Hu WH, Ching CK, et al. Treatment of Helicobacter pylori in patients with duodenal ulcer haemorrhage - a long-term randomized, controlled study. Am J Gastroenterol 2000;95:2225-32.
146. Rokkas T, Karameris A, Mavrogeorgis A, Rallis E, Giannikos N. Eradication of Helicobacter pylori reduces the possibility of rebleeding in peptic ulcer disease. Gastrointest Endosc 1995; 41:1-4.
147. Vcev A, Horvat D, Rubinic M, Stimac D, Vceva A. Uravic M, et al. Eradication of Helicobacter pylori reduces the possibility of rebleeding in duodenal ulcer disease. Acta Facultatis Medicae Fluminensis 1996;21(2):59-65 (in Serbocroat).
148. Riemann JF, Schilling D, Schauwecker P, Wehlen G, Dorlars D, Kohler B, et al. Cure with omeprazole plus amoxicillin versus long-term ranitidine therapy in Helicobacter pylori-associated peptic ulcer bleeding. Gastrointest Endosc 1997; 46:299-304.
149. Santander C, Gravalos RG, Gomez-Cedenilla A, Cantero J, Pajares JM. Antimicrobial therapy for Helicobacter pylori infection versus long-term maintenance antisecretion treatment in the prevention of recurrent haemorrhage from peptic ulcer: prospective nonrandomized trial on 125 patients. Am J Gastroenterol 1996;91:1549-52.
150. Sung JJ, Leung WK, Suen R, Leung VK, Chan FK, Ling TK. One-week antibiotics versus maintenance acid suppression therapy for Helicobacter pylari-associated peptic ulcer bleeding. Dig Dis Sci 1997; 42:2524-8.
151. Adamek RJ, Freitag M, Opferkuch W, Ruhl GH, Wegener M. Intravenous omeprazole/amoxicillin and omeprazole pretreatment in Helicobacter pylori-positive acute peptide ulcer bleeding. A pilot study. Scand J Gastroenterol 1994;29:880-3.
152. Altorjay IF, Vitalis ZS, Szasz RR, Palatka KK, Udvardy MM. Immediate eradication of Helicobacter pylori infection seems to be beneficial compared to solely PPI treatment in the management of bleeding duodenal ulcer. Gastroenterology 2000;118:A1209.
153. Amendola M, Farias R, Katz J, Luna P, Janella M, Musi A, et al. Absence of bleeding recurrence of peptic ulcer after long term follow-up of successful eradication of Helicobacter pylori. Acta Gastroenterol Latinoam 1999;29:47-50.
154. Arkkila PE, Farkkila MA, Kosunen T, Nuutinen HU, Sipponen R Seppala K. The role of Helicobacter pylori eradication in bleeding peptic ulcer healing, relapse and rebleeding: a randomised controlled trial. Gastroenterology 2001;120 (Suppl 1):2962.
155. Capurso G, Annibale B, Osborn J, D'Ambra G, Martino G, Lahner E, et al. Occurrence and relapse of bleeding from duodenal ulcer: respective roles of acid secretion and Helicobacter pylori infection. Aliment Pharmacol Ther 2001; 15:821-9.
156. Chan FK, Sung JJ, Chung SC, To KF, Yung MY, Leung VK, et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997;350:975-9.
157. Chan FK, Sung JJ, Suen R, Lee YT, Wu JC, Leung WK, et al. Does eradication of Helicobacter pylori impair healing of nonsteroidal anti-inflammatory drug associated bleeding peptic ulcers? A prospective randomized study. Aliment Pharmacol Ther 1998;12:1201-5.
158. Chan FK, Chung SC, Suen BY, Lee YT, Leung WK, Leung VK, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001; 344:967-73.
159. Chan FK, To KF, Wu JC, Yung MY, Leung WK, Kwok T, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflarnmatory drugs: a randomised trial. Lancet 2002; 359:9-13.
160. Chan FKL, Wu JCY, Suen BY, Leung W, To KF, Hung LCT, et al. Eradication of H. pylori to prevent recurrent ulcer complications associated with low-dose aspirin: a long-term cohort study. Gastroenterology 2002;122:A86.
161. Chen CY, Chang TT, Lin XZ. Intravenous omeprazole plus antibiotics in 215 Helicobacter related peptic ulcer patients with major stigmata of recent haemorrhage - a preliminary report of a randomized controlled trial. Gut 1996; 39 (Suppl 3):A141 (abstract).
162. Chen CY, Sm MZ, Lee SC, Short-term and long-term effect of new triple therapy in Helicobacter-related ulcer bleeding with major stigmata of recent haemorrhage. Gastroenterology 1998;114:A89.
163. Di Mario F, Salandin S, Kusstatscher S, Dal Bo N, Buda A, Franceschi M, et al. Eradication of Helicobacter Pylori (Hp) infection in preventing peptic ulcer bleeding. Gut 1997;41 (Suppl 3):A203.
164. Fakhreih S, Rahemi M, Dehbashi N, Firoozi MS, Keshavarz AA, Albborzi I, et al. Eradication of Helicobacter pylori vs. ranitidine maintenance therapy for prevention of duodenal ulcer rebleeding. Gut 1995;37 (Suppl 2):A236.
165. Gisbert JP, Boixeda D, Hernandez Ranz F, de Martin Argila C. [Eradication of Helicobacter pylori and hemorrhagic recurrence of duodenal ulcer]. Rev Esp Enferm Dig 1995;87:910-11 (in Spanish).
166. Gisbert JP, Boixeda D, Aller R, de la Serna C, Sanz E, de Martin Argila C, et al. [Helicobacter pylori and digestive haemorrhage due to duodenal ulcer: the prevalence of the infection, the efficacy of 3 triple therapies and the role of eradication in preventing a hemorrhagic recurrence]. Med Clin (Barc) 1999;112:161-5 (in Spanish).
167. Hsieh YH, Lin HJ, Tseng GY, Perng CL, Chang FY, Lee SD. A 3-day anti- Helicobacter pylori therapy is a good alternative for bleeding peptic ulcer patients with Helicobacter pylori infection. Hepatogastroenterology 2001;48:1078-81.
168. Huelin Benitez J, Jimenez Perez M, Duran Campos A, España Contreras P, Lozano Rey JM, et al. Haemorrhagic relapse in duodenal ulcers after eradication of Helicobacter pylori. Gut 1998; 43 (Suppl 2):A101.
169. Jaspersen D, Korner T, Schorr W, Hammar C-H. [Helicobacter pylori associated duodenum ulcer bleeding. Germ eradication with drugs is an useful therapy]. Krankenhausarzt 1994;67:234-6 (in German).
170. Jaspersen D, Korner T, Schorr W, Hammar C-H. Helicobacter pylori-associated duodenal ulcer bleeding. Results of eradication treatment with omeprazole and amoxicillin. Munch Med Wochenschr 1994;136:625-7.
171. Jaspersen D, Korner T, Schorr W, Brennenstuhl M, Heinz-Hammar C. Omeprazole-amoxycillin therapy for eradication of Helicobacter pylori in duodenal ulcer bleeding: preliminary results of a pilot study. J Gastroenterology 1995;30:319-21.
172. Krizman I, Ribnikar M, Kozjek F, Primozic S. Comparative amoxicillin-azithromycin treatment of Helicobacter pylori positive patients with bleeding duodenal ulcer. Acta Pharm 1997; 47:183-8.
173. Kung NN, Sung JJ, Yuen NW, Ng PW, Wong KC, Chung EC, et al. Anti- Helicobacter pylori treatment in bleeding ulcers: randomized controlled trial comparing 2-day versus 7-day bismuth quadruple therapy. Am J Gastroenterol 1997;92:438-41.
174. Labenz J, Borsch G. Role of Helicobacter pylori eradication in the prevention of peptic ulcer bleeding relapse. Digestion 1994; 55:19-23.
175. 2-antagonist is not necessary after eradication of Helicobacter pylori in bleeding peptic ulcers. Gastroenterology 1998; 114:A192.
176. Lai KC, Hui WM, Wong BC, Hu WH, Lam SK. Ulcer-healing drugs are required after eradication of Helicobacter pylori in patients with gastric ulcer but not duodenal ulcer haemorrhage. Aliment Pharmacol Ther 2000;14:1071-6.
177. Lee CL, Tu TC, Wu CH, Chen TK, Chan CC, Huang SH, et al. One-week low-dose triple therapy is effective in treating Helicobacter pylori-infected patients with bleeding peptic ulcers. J Formos Med Assoc 1998;97:733-7.
178. Lee CL, Wu CH, Chen TK, Tu TC, Chan CC, Lee SC. Maintenance anti-ulcer treatment is not necěssary in patients with bleeding peptic ulcer after H. pylori eradication and ulcer healing. Gut 1999; 45 (Suppl 3):A116.
179. Lin HJ, Tseng GY, Hsieh YH, Perng CL, Lee FY, Chang FY, et al. Will Helicobacter pylori affect short-term rebleeding rate in peptic ulcer bleeding patients after successful endoscopic therapy? Am J Gastroenterol 1999;94:3184-8.
180. Loperfido S, Priora R, Monica F, Salvat HH. Effect of Helicobacter pylori eradication on recurrence of bleeding duodenal ulcer and dyspeptic symptoms: a two-year prospective study. Gastroenterology 2001;120:A585.
181. Macri G, Milani S, Surrenti E, Passaleva MT, Salvadori G, Surrenti C. Eradicacion of Helicobacter pylori reduces the rate of duodenal ulcer rebleeding: a long-term follow-up study. Am J Gastroenterol 1998;93:925-7.
182. Martino G, Paoletti M, Annibale B, Marcheggiano A. Marignani M, Luzzi I, et al. Duodenal ulcer and Helicobacter pylori: relapse and recurrence in a long-term stuay. Gastroenterology 1998; 114:A219.
183. Pamos S, Lujan M, Canelles P, Orti E, Quiles F, Tome A, et al. Erradicación del Helicobacter pylori y recidiva hemorrágica por ulcus gástrico. Rev Esp Enferm Dig 1998;90 (Suppl 1):136.
184. Pauly MP, Nason DT, Spinka P, Fecha RE, Trudeau W. Antibiotic therapy does not eliminate the risk of rebleeding in Helicobacter pylori-positive patients with upper GI haemorrhage. Gastroenterology 1997;112:A125.
185. Pazzi P, Dalla Libera M, La Froscia A, Carli G, Scagliaini R, Merighi A, et al. Helicobacter pylori eradication reduces rebleeding rate in peptic ulcer disease. Gastroenterology 1996;110:A224 (abstract).
186. Pazzi P, Scagliarini R, Gamberini S, Rizzo C, Gullini S. Helicobacter pylori (Hp) eradication and reduction of duodenal ulcer (DU) bleeding relapse: a 4-year follow-up study. Gastroenterology 1999; 116:A278.
187. Pellicano R, Peyre S, Leone N, Repici A, De Angelis C, Rizzi R, et al. The effect of the eradication of Helicobacter pylori infection on haemorrhage because of duodenal ulcer. J Clin Gastroenterol 2001;32:222-4.
188. Pica R, Marigani M, D'Ambra G, Cavilia R, Antonelli G, Annibale B, et al. One year H. pylori eradication in duodenal ulcer (DU) hypersecretory patients does not alter acid secretion but prevents ulcer relapse and bleeding. Gastroenterology 1996; 111:A250 (abstract).
189. Romero Gomez M, Martinez Delgado C, Grande L, Otero Fernandez MA, Vargas J, Castro Fernandez M. Intravenous eradication therapy for bleeding gastro duodenal ulcer associated with Helicobacter pylori infection. Rev Esp Enferm Dig 2000;92:386-91.
190. Ruiz Gomez F, Sanchez Serrano FJ, Martinez Egea A, Del Garcia Castillo G, Sanchez Cuenca J, Coronas Planas M. Intravenous 3-day Helicobacter pylori eradication therapy is highly effective in patients with bleeding peptic ulcer. Gastroenterol Hepatol 2002;25:383-6.
191. Seppala K, Haapiainen R, Sipponen P, Halttunen J, Färkkilä M, Sarna S, et al. Two week antimicrobials and omeprazole therapy is sufficient to cure Helicobacter pylori positive bleeding peptic ulcer - a randomized trial. Gut 1995;37 (Suppl 2):A193.
192. Sheu BS, Yang HB, Su IJ, Shiesh SC, Chi CH, Lin XZ. Bacterial density of Helicobacter pylori predicts the success of triple therapy in bleeding duodenal ulcer. Gastrointest Endosc 1996; 44:683-8.
193. Sheu BS, Chi CH, Yang HB, Jen CM, Lin XZ. A three-day course of intravenous omeprazole plus antibiotics for H. pylori-positive bleeding duodenal ulcer. Hepatogastroenterolgy 1999; 46:2363-71.
194. Siu WT, Luk YW, Kwok ASY, Law BKB, Chau CH, Lao WC, et al. Ulcer healing drug is not necessary after eradication of Helicobacter pylori in bleeding duodenal ulcer. Gastroenterology 1999; 116:A313.
195. Sonnenberg. A, Olson CA, Zhang J. The effect of antibiotic therapy on bleeding from duodenal ulcer. Am J Gastroenterol 1999; 94(4):950.
196. van der Voort PH, van der Hulst RW, Zandstra DF, Geraedts AA, van der Ende A, Tytgat GN. Suppression of Helicobacter pylori infection during intensive care stay: related to stress ulcer bleeding incidence? J Crit Care 2001;16:182-7.
197. Vergara M, Casellas F, Saperas E, de Torres I, Lopez J, Borruel N, et al. Helicobacter pylori eradication preyents recurrence from peptic ulcer haemorrhage. Eur J Gastroenterol Hepatol 2000; 12:733-7.
198. Agrawal NM, Roth S, Graham DY, White RH, Germain B, Brown JA, et al. Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer: a randomized, controlled trial. Ann Intern Med 1991;115:195-200.
199. Agrawal NM, Van Kerckhove HEJM, Erhardt LJ, Geis GS. Misoprostol coadministered with diclofenac for prevention of gastro duodenal ulcers: a one-year study. Dig Dis Sci 1995; 40:1125-31.
200. Berkõwitz JM, Rogenes PR, Sharp JT, Warner CW. Ranitidine protects against gastro duodenal mucosal damage associated with chronic aspirin therapy. Arch Intern Med 1987;147:2137-9.
201. Bianchi Porro G., Lazzaroni M., Imbesi V., Montrone F., Santagada T. EfIficacy of pantoprazole in the prevention of peptic ulcers, induced by non-steroidal anti-inflammatory drugs: a prospective, placebo-controlled, double-blind, parallel-group study. Dig Liver Dis 2000;32:201-8.
202. Bocanegra TS, Weaver AL, Tindall EA, Sikes DH, Ball JA, Wallemark CB, et al. Diclofenac/misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or hip: a randomized, placebo controlled trial. J Rheumatol 1998; 25:1602-11.
203. Bolten W, Melo Gomes JA, Stead H, Geis GS. The gastro duodenal safety and efficacy of the fixed combination of diclofenac and misoprostol in the treatment of osteoarthritis. Br J Rheumatol 1992; 31:753-8.
204. Chan FKL, Sung JJY, Ching JYL, Wu JCY, Lee YT, Leung WK, et al. Randomized trial of low-dose misoprostol and naproxen vs. nabumetone to prevent recurrent upper gastrointestinal haemorrhage in users of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2001; 15:19-24.
205. Chan FKL, Leung WX, Suen BY, Lee K, Lee YT, WU JCY, et al. A double-blind randomized comparison of celecoxib vs. omeprazole and diclofenac for secondary prevention of ulcer bleeding in chronic NSAID users. Gastroenterology 2001;120 (5 Suppl 1):A143 (abstract).
206. Chandrasekaran AN, Sambandam PR, Lal HM, Ramakrishnan S, Porkodi R, Krishnamurthy V, et al. Double blind, placebo controlled trial on the cytoprotective effect of misoprostol in subjects with rheumatoid arthritis, osteoarthritis and seronegative spondarthropathy on NSAIDs. J Assoc Phys India 1991;39:919-21.
207. Cullen D, Bardhan KD, Eisner M, Kogut DG, Peacock RA. Thomson JM, et al. Primary gastro duodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther 1998;12:135-40.
208. Delmas PD, Lambert R, Capron MH. [Misoprostol in the prevention of gastric erosions caused by nonsteroidal anti-inflammatory agents]. Revue du Rhumatisme Edition Francaise 1994;61:126-31 (in French).
209. Ehsanullah RSB, Page MC, Tildesley G, Wood JR. Prevention of gastro duodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. BMJ 1988;297:1017-21.
210. Ekstrom P, Carling L, Wetterhus S, Wingren PE, Anker-Hansen O, Lundegardh G, et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study. Scand J Gastroenterol 1996;31:753-8.
211. Elliott SL, Yeomans ND, Buchanan RR, Smallwood RA. Efficacy of 12 months' misoprostol as prophylaxis against NSAID-induced gastric ulcers. A placebo-controlled trial. Scand J Rheumatol 1994; 23:171-6.
212. Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet 1988;ii:1277-80.
213. Graham DY, White RH, Moreland LW, Schubert. TT, Katz R, Jaszewski R, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAlDs. Ann Intern Med 1993; 119:257-62.
214. Graham DY, Agrawal NM, Campbell DR, Haber MM, Collis C, Lukasik NL, et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs. lansoprazole. Arch Intern Med 2002;162:169-75.
215. Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Swannell AJ, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs. Omeprazole versus Misoprostol for NSAID, induced ulcer Management (OMNIUM)Study Group. N Engl J Med 1998;338:727-34.
216. Henriksson K, Uribe A, Sandstedt B, Nord CE. Helicobacter pylori infection, ABO blood group, and effect of misoprostol on gastro duodenal mucosa in NSAID-treated patients with rheumatoid arthritis. Dig Dis Sci 1993;38:1688-96.
217. Hudson N, Taha AS, Russell RI, Trye P, Cottrell J, Mann SG, et al. Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastro duodenal ulceration. Gastroenterology 1997;112:1817-22.
218. Jensen D, Ho S, Hamamah S, Frankl H, Faigel D, DeMarco D, et al. A randomized study of omeprazole compared to misoprostol for prevention of recurrent ulcers and ulcer haemorrhage in high risk patients ingesting aspirin or NSAIDs. Gastroenterology 2000; 118(4 Pt 2):A892 (abstract).
219. Levine LR, Cloud ML, Enas NH. Nizatidine prevents peptic ulceration in high-risk patients taking nonsteroidal anti-inflammatory drugs. Arch Intern Med 1993;153:2449-54.
220. Melo Gomes JA, Roth SH, Zeeh J, Bruyn GAW, Woods EM, Geis GS. Double-blind comparison of efficacy and gastro duodenal safety of diclofenac/misoprostol, piroxicam, and naproxen in the treatment of osteoarthritis. Ann Rheuem Dis 1993;52:881-5.
221. Raskin JB, White RH, Jackson JE, Weaver AL, Tindall EA, Lies RB, et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med 1995;123:344-50.
222. Raskin JB, White RH, Jaszewski R, Korsten MA. Schubert TT, Fort JG. Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospective, double-blind, multicenter study. Am J Gastroenterol 1996;91:223-6.
223. Robinson MG, Griffin JW Bowers J, Kogan FJ, Kogut DG, Lanza FL. et al. Effect ot ranitidine gastro duodenal mucosal damage induced by nonsteroidal anti-inflammatory drugs. Dig Dis Sci 1989; 34:424-8.
224. Robinson M, Mills RJ, Euler AR. Ranitidine prevents duodenal ulcers associated with non-steroidal anti-inflarnmatory drug therapy. Aliment Pharmarol Ther 1991;5:143-50.
225. Roth SH, Bennett RE, Mitchell CS, Hartman RJ. Cimetidine therapy in nonsteroidal anti-inflammatory drug gastropathy. Double-blind long-term evalution. Arch Intern Med 1987; 147:1798-801.
226. Roth SH, Tindall EA, Jain AK, McMahon FG, April PA, Bockow BI, et al. A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misopostol on the upper gastrointestinal tract mucosa. Arch Intern Med 1993;153:2565-71.
227. Saggioro A, Alvisi V, Blasi A, Dobrilla G, Fioravanti A, Marcolengo R.'Misoprostol prevents NSAID-induced gastro duodenal lesions in patients with osteoarthritis and rheumatoid arthritis. Ital J Gastroenterol 1991;23:119-23.
228. Simon B, Muller P. Nizatidine in therapy and prevention of non-steroidal anti-inflammatory drug-induced gastro duodenal ulcer in rheumatic patients. Scand J Gastroenterol (Suppl) 1994; 286:25-8.
229. Swift GL, Heneghan M, Williams GT, Williams BD, O'Sullivan MM, Rhodes J. Effect of ranitidine on gastro duodenal mucosal damage in patients on long-term non-steroidal anti-inflammatory drugs. Digestion 1989; 44:86-94.
230. Taha AS, Hudson N, Hawkey CJ, Swannell AJ, Trye PN, Cottrell J, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal anti-inflammatory drugs. N Engl J Med 1996;334:1435-9.
231. ten Wolde S, Dijkmans BA, Janssen M, Hermans J, Lamers CB. High-dose ranitidine for the prevention of recurrent peptic ulcer disease in rheumatoid arthritis patients taking NSAIDs. Aliment Pharmacol Ther 1996;10:347-51.
232. Valentini M. Cannizzaro R, Poletti M, Bortolussi R, Fracasso A, Testa V, et al. Nonsteroidal anti-inflammatory drugs for cancer pain: comparison between misoprostol and ranitidine in prevention of upper gastrointestinal damage. J Clin Oncol 1995;13:2637-42.
233. Van Groenendael JH, Markusse HM, Dijkmans BA, Breedveld FC. The effect of ranitidine on NSAID related dyspeptic symptoms with and without peptic ulcer disease of patients with rheumatoid arthritis and osteoarthritis. Clin Rheumatol 1996; 15:450-6.
234. Verdickt W, Moran C, Hantzschel H, Fraga AM, Stead H, Geis GS. A double-blind comparison of the gastro duodenal safety and efficacy of diclofenac and a fixed dose combination of diclofenac and misoprostol in the treatment of rheumatoid arthritis. Scand J Rheumatol 1992; 21:85-91.
235. Yeomans ND, Tulassay Z, Juhasz L, Racz I, Howard JM, Van Rensburg CJ, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998; 338:719-26.
236. Agrawal NM, Caldwell J, Kivitz AJ, Weaver AL, Bocanegra TS, Ball J, et al. Comparison of the upper gastrointestinal safety of Arthrotec(TM) 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers. Clin Ther 1999;21:659-74.
237. Agrawal NM, Campbell DR, Safdi MA, Lukasik NL, Huang B, Haber MM. Superiority of lansoprazole vs. ranitidine in heating nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group. Arch Intern Med 2000;160:1455-61.
238. Bianchi Porro G, Lazzaroni M, Petrillo M. Double blind, double dummy endoscopic comparison of the mucosal protective effect of misoprostol versus ranitidine on naproxen-induced mucosal injury to the stomach and duodenum. in rheumatic patients. Am J Gastroenterol 1997; 92:663-7.
239. Bianchi Porro G, Lazzaroni M, Petrillo M, Manzionna G, Montrone F, Caruso I. Prevention of gastro duodenal damage with omeprazole in patients receiving continuous NSAIDs treatment, A double blind placebo controlled study. Ital J Gastroenterol Hepatol 1998; 30:43-7.
240. Caldwell JR, Weaver AL, Brown SK, McCormack GH. Endoscopic evaluation of rioprostil in the management of non-steroidal anti-inflammatory drug-induced gastritis: an interim analysis. Scand J Gastroenterol (Suppl) 1989; 24:239-11.
241. Daneshmend TK, Stein AG, Bhaskar NK, Hawkey CJ. Abolition by omeprazole of aspirin induced gastric mucosal injury in man. Gut 1990; 31:514-17.
242. Donnelly MT, Goddard AF, Filipowicz B, Morant SV, Shield MJ, Hawkey CJ. Low-dose misoprostol for the prevention of low-dose aspirin-induced gastro duodenal injury. Aliment Pharmacol Ther 2000; 14:529-34.
243. Geis G, Stead MWC, Nicholson P. Prevalence of mucosal lesions in the stomach and duodenum due to chronic use of NSAID in patients with rheumatoid arthritis or osteoarthritis, and interim report on prevention by misoprostol of diclofenac-associated lesions. J Rheumatol:1991; 18:11-14.
244. Geis GS. Overall safety of Arthrotec. Scand J Rheumatol (Suppl) 1992;21(96):33-6.
245. Melo Gomes JA. The safety of Arthrotec(TM) in patients with rheumatoid arthritis or osteoarthritis: an assessment of the upper gastrointestinal tract by endoscopy. Scand J Rheumatol (Suppl) 1992; 21(96):23-31.
246. Rose P, Huang B, Lukasik N, Collis C. Evidence that lansoprazole is effective in preventing NSAID induced ulcers. Gastroenterology 1999;116:A295 (abstract).
247. Rugstad HE, Giercksky KE, Husby G, Holme I. Effect of cimetidine on gastrointestinal symptoms in patient taking nonsteroidal anti-inflammatory drugs: a large double-blind placebo controlled study. Scand J Rheumatol 1994;23: 177-81.
248. Ryan JR, Vargas R. Clay GA, McMahon FG. Role of misoprostol in reducing aspirin-induced gastrointestinal blood loss in arthritic patients. Am J Med 1987;83 (Suppl 1A):41-4 (abstract).
249. Walan A, Bader J-P, Classen M, Lamers CBHW, Piper DW, Rutgersson K, et al. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med 1989;320:69-75.
250. Cohen DL, Gompel H, Baranes C, Bornstein U, Brajer S, Cambray S, et al. Two comparative studies of dosmalfate vs. misoprostol in the prevention of NSAID-induced gastric ulcers in rheumatic patients. Drugs Today 2000; 36 (Suppl A):73-8.
251. 2-blocker therapy. Am J Med 1987; 83 (Suppl 1A):27-31.
252. Centre for Health Services Research. Dyspepsia: Managing dyspepsia in adults in primary care. Report No. 112. Newcastle upon Tyne: University of Newcastle upon Tyne; 2004.
253. Government Actuary's Department. URL:http://www.gad.gov.uk/Life_Tables/ Interim_life_tables.htm. Accessed 18 September 2007.
254. Office for National Statistics. Office for National Statistics Annual, on-line edition. URL:http://www.statistics.gov.uk/stathase/ Product.asp?vink=618. Accessed 18 September 2007.
255. Macran S, Weatherly H, Kind P. Measuring population health: a comparison of three generic health status measures. Med Care 2003; 41:218-31.
256. Prescription Pricing Authority. URL:http://www.ppa.org.uk/ppa/edt. Accessed 18 September 2007.
257. Dorward S, Sreedharan A, Leontiadis GI, Howden CW, Moayyedi P, Forman D. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in tipper gastrointestinal bleeding Cochrane Database Syst Rev 2006;(4):CD005415.
258. Hawkey CJ, Tulassay Z, Szczepanski L, Van Rensburg CJ, Filipowicz-Sosnowska A, Lanas A, et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Lancet 1998;352:1016-21.
259. Labenz J, Blum AL, Bolten WW, Dragosics B, Rosch W, Stolte M, et al. Primary prevention of diclofenac associated ulcer and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised double blind, placebo controlled, clinical trial. Gut 2002; 51:329-35.
260. Pilotto A, Di Mario F, Franceschi M, Leandro G, Battaglia G, Germana B, et al. Pantoprazole versus one-week Helicobacter pylori eradication therapy for the prevention of acute NSAID-related gastro duodenal damage in elderly subjects. Aliment Pharmacol Ther 2000;14:!077-82.
261. Lai KC, Lau CS, Ip WY, Wong BCY, Hui WM, Hu WHC, et al. Effect of treatment of Helicobacter pylori on the prevention of gastro duodenal ulcers in patients receiving long-term NSAIDs: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2003; 17:799-805.
262. Giral A, Ozdogan O, Celikel CA, Tozun N, Ulusoy NB, Kalayci C. Effect of Helicobacter pylori eradication on anti-thrombotic dose aspirin-induced gastro duodenal mucosal injury. J Gastroenterol Hepatol 2004;19(7):773-7.
263. Singh G, Triadafilopoulos G. Appropriate choice of proton pump inhibitor therapy in the prevention and management of NSAID-related gastrointestinal damage. Int J Clin Pract 2005; 59:1210-17.
264. Bianchi Porro G, Parente F, Imbesi V, Montrone F, Caruso I. Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users. Response to omeprazole dual therapy. Gut 1996;39:22-6.
265. Papatheodoridis GV, Papadelli D, Cholongitas E, Vassilopoulos D, Mentis A, Hadziyannis SJ. Effect of Helicobacter pylori infection on the risk of upper gastrointestinal bleeding in users of nonsteroidal anti-inflammatory drugs. Am J Med 2004; 116:601-5.
266. Vergara M, Gisbert JP, Calvet X. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005;21:1411-18.